Review article

DOI: 10.3345/kjp.2010.53.9.830
Korean J Pediatr 2010;53(9):830-833

Change in the treatment strategy for pediatric Crohn’s disease

Mi Jin Kim, M.D. and Yon Ho Choe, M.D.

Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

Crohn’s disease is characterized by chronic inflammation involving any portion of the gastrointestinal tract. Treating Crohn’s disease is a major challenge for clinicians, as no curative therapy currently exists. Pediatric Crohn’s disease is characterized by frequent relapses, a wide extent of disease, a high prevalence of extraintestinal manifestations, and a severe clinical course. The classic therapeutic approach is known as the ‘step-up’ strategy, and follows a progressive course of treatment intensification as disease severity increases. Although this approach is usually effective for symptom control, many patients become either resistant to or dependent on corticosteroids. The efficacy of infliximab suggests that, rather than a progressive course of treatment, early intense induction may reduce complications associated with conventional treatment and improve quality of life. Intensive early therapy with infliximab is known as the ‘top-down’ strategy. Such therapy offers the potential for altering the natural history of Crohn’s disease, and is changing treatment paradigms. However, the relatively new concept of an early aggressive or ‘top-down’ treatment approach is not yet widely accepted, especially in pediatric patients. The results of our current study demonstrate that early and intensive treatment of pediatric Crohn’s disease patients with infliximab, at initial diagnosis, was more effective for maintaining remission and reducing flares.

Key words: Crohn’s disease, Child, Treatment

Introduction

Crohn’s disease (CD) is characterized by chronic inflammation involving any portion of the gastrointestinal tract. Although the etiology of CD remains incompletely understood, environmental factors, infectious microbes, ethnic origin, genetic susceptibility, and immune system dysfunction have been implicated in the associated chronic mucosal inflammation. Treating CD is a major challenge for clinicians, as no curative therapy currently exists. The classic therapeutic approach is known as the “step-up” strategy, and follows a progressive course of treatment intensification as disease severity increases (Fig. 1).

Conventional therapy for active disease includes treatment with corticosteroids. Initially, corticosteroids are very effective...
and fast acting; however, long-term exposure to corticosteroids leads to drug dependency and/or resistance. Several randomized, placebo-controlled studies have demonstrated that the biological drug infliximab (Remicade: Centocor Ortho Biotech, Malvern, PA, USA), a monoclonal immunoglobulin G1 chimeric antibody directed against tumor necrosis factor-α, is highly effective in improving the clinical course in patients with CD. Since receiving FDA approval for pediatric use in May 2006, infliximab has been widely used in pediatric patients with CD. The efficacy of infliximab suggests that, rather than a progressive course of treatment, early intense induction may reduce complications associated with conventional treatment and improve quality of life. Intensive early therapy with infliximab is known as the “top-down” strategy (Fig. 1).

Ethnic differences in the clinical characteristics of CD have been noted. CD is relatively common in developed countries, whereas it is not as common in Asian countries. In addition, recent studies from Far East Asian countries reveal that the prevalence of NOD2 mutations, associated with increased susceptibility to CD in Western populations, is lower than that found in other populations. Therefore, the clinical response to treatment for CD in Asian countries might differ from patients in Western countries.

**Step-up strategy**

Pediatric CD is characterized by frequent relapses, wide disease extent, high prevalence of extraintestinal manifestations, and severe clinical course. Current practice guidelines recommend that most patients with active disease should initially be treated with corticosteroids. Although this approach is usually effective for symptom control, many patients become either resistant to or dependent on these drugs. Long-term exposure to corticosteroids is also associated with complications such as Cushing’s syndrome, and therefore, with increased risk of mortality. For this reason, most clinicians initiate treatment with corticosteroid-sparing drugs such as azathioprine, mercaptopurine, or methotrexate once corticosteroid resistance or dependence develops.

Infliximab is an anti-tumor necrosis factor (TNF-α) monoclonal antibody that was initially used in corticosteroid-dependent and corticosteroid-refractory CD. TNF-α is a pro-inflammatory cytokine that plays a key role in the pathophysiology of a number of inflammatory disorders, including CD. The use of infliximab has been well documented as an effective treatment for moderate to severe CD in children in several studies. Infliximab, as a scheduled treatment, is effective for the induction and maintenance of remission in patients with CD (Fig. 1).

**Top-down strategy**

Early use of infliximab with immunosuppressants, known as top-down therapy, in patients with newly diagnosed CD has resulted in better outcomes in adult patients. An 8-week maintenance treatment schedule with infliximab has been shown to be a cost-effective approach in adult patients with active luminal or fistulizing CD. Such therapy offers the potential for altering the natural history of CD, and is changing treatment paradigms. One possible explanation for the prolonged remission with infliximab treatment is that this medication might help heal mucosal lesions in patients with severe disease as well as those with mild disease. However, the relatively new concept of an early aggressive or top-down treatment approach is not yet widely accepted, especially in pediatric patients, even although some studies have reported that infliximab is more effective in children than in adults (Fig. 1).

**The safety of infliximab**

The safety profile of infliximab is an important issue, as its use and indications are rapidly increasing. Infliximab treatment appears to be well tolerated, however, anaphylactic reactions and symptoms caused by immunosuppression, such as upper respiratory tract infections, herpes zoster activation, severe acute bacterial infections, and an increased risk of tuberculosis, have all been described following treatment with infliximab. Pretreatment before infliximab infusion may be helpful in ameliorating these side effects. Little is known about the potential for long-term toxicity in infliximab therapy. After repeated dosing is performed, some patients have human antibodies to chimeric TNF-α antibodies. Repeated administration of chimeric antibodies may be associated with the formation of autoimmune antibodies and a self-limited
The development of lymphoma has been reported as a possible, although rare, long-term complication of anti-TNF therapy in patients with rheumatoid arthritis and CD\textsuperscript{36–38}. Several reports of a possible association between concomitant infliximab and immunomodulator therapy and hepatosplenic T-cell lymphoma (HSTCL) have emerged\textsuperscript{37, 38}. However, the mechanism of this possible association remains unclear. Until further evidence emerges, long-term surveillance of patients who have used infliximab in combination with immunomodulators is warranted.

The experience in Samsung Medical Center

We have used infliximab as an induction therapy since 2005. Our patients had a better response to infliximab treatment than compared to conventional therapy. At 8 weeks, remission was achieved in 3 of 11 patients (27.3%) in the step-up group, and in 16 of 18 patients (88.9%) in the top-down group. At 1 year of follow-up, remission was maintained in 5 of 11 patients (45.5%) and in 15 of 18 patients (83.3%) in the step-up and top-down groups, respectively\textsuperscript{39}. At the 1 year follow-up, the relapse rate (23.1%, 3 of 13 patients) in the top-down group was lower than that (61.5%, 8 of 13 patients) in the step-up group ($P=0.047$). At 2 years follow-up, the relapse rate (38.5%, 5 of 13 patients) in the top-down group was lower than that (76.9%, 10 of 13 patients) in the step-up group ($P=0.047$)\textsuperscript{40}. The mechanism(s) by which the top-down strategy yields superior results when compared to step-up treatment with regard to remission rates remains unclear. However, it is suggested that the patients in the step-up group had a much longer duration of disease and that they were exposed to more extensive tissue damage. Limbergen et al.\textsuperscript{15} reported that infliximab treatment early in the disease course may avoid the irreversible tissue damage often found in later stages of CD. The potential of infliximab to not only induce but also maintain remission is now well studied in adult and pediatric CD cohorts\textsuperscript{5, 6, 24}.

Conclusion

The incidence and prevalence of CD in Korea is lower than in developed countries; however, it is rapidly increasing. There is no known cure for CD. Therefore, the goal of treatment is to mitigate inflammation and the associated clinical symptoms. The current treatment guidelines are designed to maintain remission after induction therapy.

According to our experience, early and intensive treatment of pediatric CD patients with infliximab, at initial diagnosis, was more effective for maintaining remission and reducing flares.

References

1. Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature 2007;448:427–34.
2. Markowitz J, Hyams J, Mack D, Leleiko N, Evans J, Kugathasan S, et al. Corticosteroid therapy in the age of infliximab: acute and 1-year outcomes in newly diagnosed children with Crohn's disease. Clin Gastroenterol Hepatol 2006;4:1124–9.
3. Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997;337:1029–35.
4. Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hoegzand RA, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999;340:1398–405.
5. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002;359:1541–9.
6. Rutgeerts P, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 2004;126:402–13.
7. Cezard JP, Nouaili N, Talbotec C, Hugot JP, Gobert JG, Schmitz J, et al. A prospective study of the efficacy and tolerance of a chimeric antibody to tumor necrosis factors (Remicade) in severe pediatric Crohn disease. J Pediatr Gastroenterol Nutr 2003;36:632–6.
8. Baldassano R, Braegger CP, Escher JC, DeWoody K, Hendricks DF, Keenan GF, et al. Infliximab (REMICADE) therapy in the treatment of pediatric Crohn's disease. Am J Gastroenterol 2003;98:833–8.
9. Stephens MC, Shepanski MA, Mamula P, Markowitz JE, Brown KA, Baldassano RN. Safety and steroid-sparing experience using infliximab for Crohn's disease at a pediatric inflammatory bowel disease center. Am J Gastroenterol 2003;98:104–11.
10. Hyams JS, Lerner T, Griffiths A, Pfefferkorn M, Kugathasan S, Evans J, et al. Long-term outcome of maintenance infliximab therapy in children with Crohn's disease. Inflamm Bowel Dis 2009;15:816–22.
11. Yang SK, Yoon S, Kim JH, Park JY, Kim HY, Kim YH, et al. Epidemiology of inflammatory bowel disease in the Songpa-Kangdong district, Seoul, Korea, 1986–2005: a KASID study. Inflamm Bowel Dis 2008;14:542–9.
12. Inoue N, Tamura K, Kinouchi Y, Fukuda Y, Takahashi S, Ogura Y, et al. Lack of common NOD2 variants in Japanese patients with Crohn's disease. Gastroenterology 2002;122:86–91.
13. Hsiao CH, Wei SC, Wong JM, Lai HS, Chang MH, Ni YH. Pediatric Crohn disease: clinical and genetic characteristics in Taiwan. J Pediatr Gastroenterol Nutr 2007;44:342–6.
14. Wang YF, Zhang H, Ouyang Q. Clinical manifestations of inflammatory bowel disease: East and West differences. J Dig Dis 2007;8:121–7.
15. Van Limbergen J, Russell RK, Drummond HE, Aldhous MC, Round NK, Nimmo ER, et al. Definition of phenotypic characteristics of childhood-onset inflammatory bowel disease. Gastroenterology 2008;135:1114–22.
16. Rutgeerts P. Review article: the limitations of corticosteroid therapy in
Crohn’s disease. Aliment Pharmacol Ther 2001;15:1515-25.

17) Summers RW, Switz DM, Sessions JT Jr, Becktel JM, Best WR, Kern F Jr, et al. National Cooperative Crohn’s Disease Study: results of drug treatment. Gastroenterology 1979;77:847-69.

18) Malchow H, Ewe K, Brandes JW, Goebell H, Ehms H, Sommer H, et al. European Cooperative Crohn’s Disease Study (ECCDS): results of drug treatment. Gastroenterology 1984;86:249-66.

19) Munkholm P, Langholz E, Davidsen M, Binder V. Frequency of glucocorticoid resistance and dependency in Crohn’s disease. Gut 1994;35:360-2.

20) Faubion WA Jr, Lofrus EV Jr, Harmsen WS, Zinsmeister AR, Sandborn WJ. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 2001;121:255-60.

21) Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Diamond RH, Chen DM, et al. Serious infections and mortality in association with therapies for Crohn’s disease: TREAT registry. Clin Gastroenterol Hepatol 2006;4:621-30.

22) Singleton JW, Law DH, Kelley ML Jr, Mekhjian HS, Sturdevant RA. National Cooperative Crohn’s Disease Study: adverse reactions to study drugs. Gastroenterology 1979;77:870-82.

23) Lichtenstein GR. Approach to corticosteroid-dependent and corticosteroid-refractory Crohn’s disease. Inflamm Bowel Dis 2001;1 Suppl 1:S23-9.

24) Hyams J, Crandall W, Kugathasan S, Griffiths A, Olson A, Johannes J, et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn’s disease in children. Gastroenterology 2007;132:863-73; quiz 1125-7.

25) de Ridder L, Benninga MA, Taminiau JA, Hommes DW. Infliximab as first-line therapy in severe pediatric Crohn disease. J Pediatr Gastroenterol Nutr 2006;43:388-90.

26) Akobeng AK, Zachos M. Tumor necrosis factor-alpha antibody for induction of remission in Crohn’s disease. Cochrane Database Syst Rev 2004;CD003574.

27) Behm BW, Bickston SJ. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn’s disease. Cochrane Database Syst Rev 2008;CD006893.

28) D’Haens G, Baert F, van Assche G, Caenepeel P, Vergauwe P, Tiunyman H, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn’s disease: an open randomised trial. Lancet 2008;371:660-7.

29) Lindsay J, Punekar YS, Morris J, Chung-Faye G. Health-economic analysis: cost-effectiveness of scheduled maintenance treatment with infliximab for Crohn’s disease—modelling outcomes in active luminal and fistulizing disease in adults. Aliment Pharmacol Ther 2008;28:76-87.

30) Geboes K, Rutgeerts P, Opdenakker G, Olson A, Patel K, Wagner CL, et al. Endoscopic and histologic evidence of persistent mucosal healing and correlation with clinical improvement following sustained infliximab treatment for Crohn’s disease. Curr Med Res Opin 2005;21:1741-54.

31) Markowitz J, Grancher K, Kohn N, Lesser M, Duam F. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn’s disease. Gastroenterology 2000;119:895-902.

32) Hyams JS, Markowitz J, Wollin R. Use of infliximab in the treatment of Crohn’s disease in children and adolescents. J Pediatr 2000;137:192-6.

33) Friesen CA, Calabro C, Christenson K, Carpenter E, Welchert E, Daniel JF, et al. Safety of infliximab treatment in pediatric patients with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2004;39:265-9.

34) Elliott MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Bijl H, et al. Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis. Lancet 1994;344:1125-7.

35) Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 1998;41:1552-63.

36) Baecklund E, Ekholm A, Sparen P, Feltelius N, Klareskog L. Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study. BMJ 1998;317:180-1.

37) Burger DC, Florin TH. Hepatosplenic T-cell lymphoma following infliximab therapy for Crohn’s disease. Med J Aust 2009;190:341-2.

38) Zeidan A, Sham R, Shapiro J, Baratta A, Koaides P. Hepatosplenic T-cell lymphoma in a patient with Crohn’s disease who received infliximab therapy. Leuk Lymphoma 2007;48:1410-3.

39) Kim MJ, Lee JS, Lee JH, Kim JY, Choe YH. Infliximab therapy in children with Crohn’s disease: A one-year evaluation of efficacy comparing ‘top-down’ and ‘step-up’ strategies. Acta Paediatr 2010 Jul 7(Epub ahead of print)

40) Lee JS, Lee JH, Lee HJ, Kim MJ, Choe YH. Efficacy of early treatment with infliximab in pediatric Crohn’s disease. World J Gastroenterol 2010;16:1776-81.